Back to Search
MICHAEL MORSE, M.D.
M.D.
Hematology & Oncology Physician
NPI: 1588748479IndividualAccepts Medicare
Specialties, Licenses & Credentials
Hematology & Oncology PhysicianPrimary
Internal Medicine — Hematology & Oncology
Code: 207RH0003X
96-01013(NC)
CMS Specialties
PrimaryMEDICAL ONCOLOGY
Education
YALE UNIVERSITY SCHOOL OF MEDICINE
Class of 1990
Research & Publications (20)
Countering tumor-induced immunosuppression during immunotherapy for pancreatic cancer.
PMID 19216622·Expert Opin Biol Ther·2009
6-review
Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines.
PMID 18519811·Blood·2008
3-trial
Long term disease-free survival and T cell and antibody responses in women with high-risk Her2+ breast cancer following vaccination against Her2.
PMID 17822557·J Transl Med·2007
3-trial
Current immunotherapeutic strategies in colon cancer.
PMID 18022550·Surg Oncol Clin N Am·2007
6-review
Phase I study of immunization with dendritic cells modified with fowlpox encoding carcinoembryonic antigen and costimulatory molecules.
PMID 15837756·Clin Cancer Res·2005
3-trial
Perspectives in colorectal cancer - Sixth Annual Conference. Metastatic colorectal cancer.
PMID 16320126·IDrugs·2005
7-preclinical
A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer.
PMID 15723705·J Transl Med·2005
8-other
Technology evaluation: Rexin-G, Epeius Biotechnologies.
PMID 15844625·Curr Opin Mol Ther·2005
6-review
Technology evaluation: ipilimumab, Medarex/Bristol-Myers Squibb.
PMID 16370382·Curr Opin Mol Ther·2005
8-other
Preparation of peptide-loaded dendritic cells for cancer immunotherapy.
PMID 13679640·Mol Biotechnol·2003
8-other
Immunotherapy with autologous, human dendritic cells transfected with carcinoembryonic antigen mRNA.
PMID 12901279·Cancer Invest·2003
3-trial
Recent areas of development for dendritic cell vaccines.
PMID 15338754·Cancer Chemother Biol Response Modif·2003
6-review
38th Annual Meeting of the American Society of Clinical Oncology. 18-21 May 2002, Orlando, Florida, USA.
PMID 15989555·Expert Opin Emerg Drugs·2002
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 2100 ERWIN RD
DURHAM, NC 27710 - Phone
- (919) 620-4467
Quick Facts
- NPI
- 1588748479
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 36
- Publications
- 20
Are you this provider?
Claim Your Profile